Considerations in Inclusion or Removal of Treatments in Cancer Drug List

Assoc Prof Jamus Jerome Lim asked the Ministry for Health to outline the factors considered when deciding which treatments to include in or remove from the Cancer Drug List.
Ong Ye Kung stated that the Agency for Care Effectiveness assesses treatments for both clinical effectiveness and cost-effectiveness before inclusion in the list.
Drugs already on the list are retained unless specific issues arise, such as a company defaulting on contracts, a company requesting removal, or a safety recall.
The inclusion process prioritizes treatments that are medically beneficial and provide value for money to the healthcare system.
Removal from the list is driven by contractual, safety, or company-requested factors rather than routine reassessment.

Assoc Prof Jamus Jerome Lim asked the Ministry for Health to outline the factors considered when deciding which treatments to include in or remove from the Cancer Drug List.
Ong Ye Kung stated that the Agency for Care Effectiveness assesses treatments for both clinical effectiveness and cost-effectiveness before inclusion in the list.
Drugs already on the list are retained unless specific issues arise, such as a company defaulting on contracts, a company requesting removal, or a safety recall.
The inclusion process prioritizes treatments that are medically beneficial and provide value for money to the healthcare system.
Removal from the list is driven by contractual, safety, or company-requested factors rather than routine reassessment.

Assoc Prof Jamus Jerome Lim asked the Ministry for Health to outline the factors considered when deciding which treatments to include in or remove from the Cancer Drug List.
Ong Ye Kung stated that the Agency for Care Effectiveness assesses treatments for both clinical effectiveness and cost-effectiveness before inclusion in the list.
Drugs already on the list are retained unless specific issues arise, such as a company defaulting on contracts, a company requesting removal, or a safety recall.
The inclusion process prioritizes treatments that are medically beneficial and provide value for money to the healthcare system.
Removal from the list is driven by contractual, safety, or company-requested factors rather than routine reassessment.

Assoc Prof Jamus Jerome Lim asked the Ministry for Health to outline the factors considered when deciding which treatments to include in or remove from the Cancer Drug List.
Ong Ye Kung stated that the Agency for Care Effectiveness assesses treatments for both clinical effectiveness and cost-effectiveness before inclusion in the list.
Drugs already on the list are retained unless specific issues arise, such as a company defaulting on contracts, a company requesting removal, or a safety recall.
The inclusion process prioritizes treatments that are medically beneficial and provide value for money to the healthcare system.
Removal from the list is driven by contractual, safety, or company-requested factors rather than routine reassessment.

Summary